Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1968 1
1969 1
1970 3
1971 1
1972 1
1975 2
1980 2
1981 2
1982 1
1983 4
1984 2
1985 5
1986 5
1987 3
1988 7
1989 4
1990 4
1991 6
1992 6
1993 6
1994 8
1995 11
1996 14
1997 11
1998 9
1999 6
2000 8
2001 13
2002 12
2003 10
2004 6
2005 16
2006 10
2007 15
2008 12
2009 15
2010 12
2011 9
2012 16
2013 27
2014 21
2015 29
2016 15
2017 17
2018 15
2019 35
2020 42
2021 27
2022 24
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

494 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypotrichosis 6"
Page 1
Alopecia Areata. Current situation and perspectives.
Juárez-Rendón KJ, Rivera Sánchez G, Reyes-López MÁ, García-Ortiz JE, Bocanegra-García V, Guardiola-Avila I, Altamirano-García ML. Juárez-Rendón KJ, et al. Arch Argent Pediatr. 2017 Dec 1;115(6):e404-e411. doi: 10.5546/aap.2017.eng.e404. Arch Argent Pediatr. 2017. PMID: 29087123 Free article. Review. English, Spanish.
Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review.
Drake L, Reyes-Hadsall S, Martinez J, Heinrich C, Huang K, Mostaghimi A. Drake L, et al. JAMA Dermatol. 2023 Jan 1;159(1):79-86. doi: 10.1001/jamadermatol.2022.4867. JAMA Dermatol. 2023. PMID: 36449274
Quality was assessed with Oxford Centre for Evidence Based Medicine criteria. Outcomes of interest were disease course, both objectively and subjectively measured. Data were evaluated from January 3 to 11, 2022. ...Kimchi and cheonggukjang, vitamin D3, and Forti5 had low-q …
Quality was assessed with Oxford Centre for Evidence Based Medicine criteria. Outcomes of interest were disease course, both objectiv …
Treatment of alopecia areata: An Australian expert consensus statement.
Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, Joseph S, Chitreddy V, Gunatheesan S, Sindhu K, Sharma P, Green J, Eisman S, Yip L, Jones L, Sinclair R. Cranwell WC, et al. Australas J Dermatol. 2019 May;60(2):163-170. doi: 10.1111/ajd.12941. Epub 2018 Nov 8. Australas J Dermatol. 2019. PMID: 30411329
Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop alopecia totalis and 15% will develop alopecia universalis. The unpredictable course and psychological distress attri …
Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ult …
The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications.
Waśkiel-Burnat A, Osińska M, Salińska A, Blicharz L, Goldust M, Olszewska M, Rudnicka L. Waśkiel-Burnat A, et al. Cells. 2021 Dec 2;10(12):3397. doi: 10.3390/cells10123397. Cells. 2021. PMID: 34943905 Free PMC article. Review.
Moreover, it was shown that increased pre-treatment serum level of IL-12 was a positive, while increased serum levels of IL-4 and IL-13 were negative prognostic markers for the efficacy of diphenylcyclopropenone. In conclusion, alopecia areata is associated with the dysreg …
Moreover, it was shown that increased pre-treatment serum level of IL-12 was a positive, while increased serum levels of IL-4 and IL-13 were …
Italian Guidelines in diagnosis and treatment of alopecia areata.
Rossi A, Muscianese M, Piraccini BM, Starace M, Carlesimo M, Mandel VD, Alessandrini A, Calvieri S, Caro G, D'arino A, Federico A, Magri F, Pigliacelli F, Amendolagine G, Annunziata MC, Arisi MC, Astorino S, Babino G, Bardazzi F, Barruscotti S, Belloni Fortina A, Borghi A, Bruni F, Caccavale S, Calzavara-Pinton P, Cameli N, Cardone M, Carugno A, Coppola R, Dattola A, De Felici Del Giudice MB, Di Cesare A, Dika E, Di Nunno D, D'ovidio R, Fabbrocini G, Feliciani C, Fulgione E, Galluzzo M, Garcovich S, Garelli V, Guerriero C, Hansel K, La Placa M, Lacarrubba F, Lora V, Marinello E, Megna M, Micali G, Misciali C, Monari P, Monfrecola G, Neri I, Offidani A, Orlando G, Papini M, Patrizi A, Piaserico S, Rivetti N, Simonetti O, Stan TR, Stingeni L, Talamonti M, Tassone F, Villa L, Vincenzi C, Fortuna MC. Rossi A, et al. G Ital Dermatol Venereol. 2019 Dec;154(6):609-623. doi: 10.23736/S0392-0488.19.06458-7. Epub 2019 Sep 26. G Ital Dermatol Venereol. 2019. PMID: 31578836 Free article.
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. ...
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable a …
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, Sullivan-Whalen M, Singer GK, Garcet S, Pavel AB, Lebwohl MG, Krueger JG. Guttman-Yassky E, et al. Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6. Allergy. 2022. PMID: 34460948 Free PMC article. Clinical Trial.
After 48 weeks of dupilumab treatment, 32.5%, 22.5% and 15% of patients achieved SALT(30) /SALT(50) /SALT(75) improvement, respectively, while in patients with baseline IgE 200 IU/ml response rates increased to 53.8%, 46.2%, and 38.5%, respectively. Moreover, baseline IgE pred …
After 48 weeks of dupilumab treatment, 32.5%, 22.5% and 15% of patients achieved SALT(30) /SALT(50) /SALT(75) improvement, respectively, whi …
Lichen planus - a clinical guide.
Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K. Solimani F, et al. J Dtsch Dermatol Ges. 2021 Jun;19(6):864-882. doi: 10.1111/ddg.14565. Epub 2021 Jun 7. J Dtsch Dermatol Ges. 2021. PMID: 34096678
Especially with regard to mucosal or scalp affecting LP types, which often present a recalcitrant and treatment unresponsive course, efficacious therapeutic options are still lacking. Thus, LP represents a disease with a high psychosocial burden. ...
Especially with regard to mucosal or scalp affecting LP types, which often present a recalcitrant and treatment unresponsive course, …
Microneedling in androgenetic alopecia; comparing two different depths of microneedles.
Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Faghihi G, et al. J Cosmet Dermatol. 2021 Apr;20(4):1241-1247. doi: 10.1111/jocd.13714. Epub 2020 Sep 29. J Cosmet Dermatol. 2021. PMID: 32897622

RESULTS: Compared with the baseline, a significant increase in hair count and hair thickness was observed in all three groups after completion of the treatment course (P < .05). The mean rise in hair count (P = .017) and hair thickness (P = .007) was significantly great

…
RESULTS: Compared with the baseline, a significant increase in hair count and hair thickness was observed in all three groups after completi …
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J. Sheng X, et al. Clin Cancer Res. 2021 Jan 1;27(1):43-51. doi: 10.1158/1078-0432.CCR-20-2488. Epub 2020 Oct 27. Clin Cancer Res. 2021. PMID: 33109737 Clinical Trial.
Randomized trial of aromatherapy. Successful treatment for alopecia areata.
Hay IC, Jamieson M, Ormerod AD. Hay IC, et al. Arch Dermatol. 1998 Nov;134(11):1349-52. doi: 10.1001/archderm.134.11.1349. Arch Dermatol. 1998. PMID: 9828867 Clinical Trial.
Demographic analysis showed that the 2 groups were well matched for prognostic factors. CONCLUSIONS: The results show aromatherapy to be a safe and effective treatment for alopecia areata. ...
Demographic analysis showed that the 2 groups were well matched for prognostic factors. CONCLUSIONS: The results show aromatherapy to …
494 results